64 4.3. L'efficacité clinique des ?1-bloquants ,
Medical therapy of prostatic symptoms, p.77 ,
82 8.2. Ne pas s'affoler 82 8.3. Prévention par l'alimentation et le mode de vie, ., p.83 ,
Benign prostatic hyperplasia : correlations between receptor density and biding affinity of alpha(1)-adrenoreceptors and several clinical parameters, Urol Int, vol.68, pp.246-250, 2002. ,
Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia, European Urology, vol.34, issue.3, pp.169-75, 1998. ,
DOI : 10.1159/000019706
Phytotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, The Journal of Urology, vol.179, issue.6, pp.2119-2144, 2008. ,
DOI : 10.1016/j.juro.2008.01.094
groupe d'étude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia : a 1-year randomized international study, pp.384-92, 2002. ,
Prise en charge médicale de l'hypertrophie bénigne de la prostate non compliquée, Presse Med, vol.36, pp.475-80, 2007. ,
Gray's Anatomie pour les étudiants, pp.417-428, 2006. ,
5???Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection, The Journal of Sexual Medicine, vol.5, issue.12, pp.2917-2941, 2008. ,
DOI : 10.1111/j.1743-6109.2008.01001.x
Controlled release delivery system In controlled drug delivery : designing technologies for the future by park kinam, pp.14-24, 2000. ,
Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis, The American Journal of Medicine, vol.109, issue.8, pp.654-64, 2000. ,
DOI : 10.1016/S0002-9343(00)00604-5
Uroflowmetry in elderly men, World Journal of Urology, vol.13, issue.1, pp.21-33, 1995. ,
DOI : 10.1007/BF00182661
Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia, The Prostate, vol.84, issue.4, pp.351-356, 2004. ,
DOI : 10.1016/S0167-4781(97)00122-X
Précis d'anatomie clinique, Tome IV. Editions Maloine, pp.197-205, 2005. ,
Hypertrophie bénigne de la prostate, Edition française des Laboratoires Debat, p.191, 1984. ,
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasie : the Prospective European Doxazosin and combination Therapy (PREDICT) trial, pp.61-119, 2003. ,
Anatomie physiologique de la glande prostatique ,
Etiology of benign prostatic hyperplasia, Urol Clin North Am, vol.22, pp.237-246, 1995. ,
Laboratory assessment of terazosin and alpha 1-blockade in prostatic hyperplasia, pp.21-26, 1988. ,
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasie Study Group, N Engl J Med, vol.22, pp.533-542, 1996. ,
The Long-Term Outcome of Medical Therapy for BPH, European Urology, vol.51, issue.6, pp.1522-1555, 2007. ,
DOI : 10.1016/j.eururo.2007.03.034
Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens, Urology, vol.57, issue.5, pp.999-1005, 2001. ,
DOI : 10.1016/S0090-4295(00)01052-9
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia, New England Journal of Medicine, vol.349, issue.25, pp.2387-98, 2003. ,
DOI : 10.1056/NEJMoa030656
Anatomy of the prostate: An historical survey of divergent views, The Prostate, vol.9, issue.1, pp.3-13, 1980. ,
DOI : 10.1093/ajcp/49.3.347
A review of combination therapy in patients with benign prostatic hyperplasia, Clinical Therapeutics, vol.29, issue.3, pp.387-98, 2007. ,
DOI : 10.1016/S0149-2918(07)80077-4
In : L'hypertrophie bénigne de la prostate, pp.19-22, 1991. ,
Anatomie normale de la prostate. Echographie prostatique, Editions Pradel, pp.33-39, 1990. ,
Growth factor expression in early stages of benign prostatic hyperplasia upon exposure to sustained delivery of androgens, Biomed Sci Instrum, vol.39, pp.329-334, 2003. ,
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo, Urology, vol.54, issue.4 ,
DOI : 10.1016/S0090-4295(99)00232-0
on behalf of the ARIA 3001, ARIA 3002, and ARIA 3003 study investigators, Efficacy and safety of a dual inhibitor of 5-alphareductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia, pp.434-475, 2002. ,
The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH : results from the MTOPS study, J Urol, 2005. ,
Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia, Campbell's Urology, pp.1297-1336, 2002. ,
Association of Sexual Dysfunction With Lower Urinary Tract Symptoms of BPH and BPH Medical Therapies: Results From the BPH Registry, Urology, vol.73, issue.3, pp.562-568, 2009. ,
DOI : 10.1016/j.urology.2008.05.034
Anatomie humaine descriptive, topographique et fonctionnelle ,
Imagerie de la prostate : principes, applications et perspectives, Editions Masson, pp.2-6, 2005. ,
and Other Ethnobotanical Species with Antiandrogenic Activity, Planta Medica, vol.72, issue.9, pp.807-820, 2006. ,
DOI : 10.1055/s-2006-946638
Tamsulosin, the first prostate-selective ?1 A -adrenoreceptor antagonist Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BHP), Eur Urol, vol.29, pp.145-154, 1996. ,
The effect of pygeum africanum on fibroblast growth factor (FGF) and transforming growth factor beta (TGFb1/LAP) expression in animal model, Acta Microbiologica et Immunologica Hungarica, vol.48, issue.1, pp.1-9, 2001. ,
DOI : 10.1556/AMicr.48.2001.1.1
The Natural History of Lower Urinary Tract Symptoms over Five Years, European Urology, vol.43, issue.4, pp.374-380, 2003. ,
DOI : 10.1016/S0302-2838(03)00084-8
Relationship Between Age, Prostate Volume, Prostate-specific Antigen, Symptom Score and Uroflowmetry in Men with Lower Urinary Tract Symptoms, Scandinavian Journal of Urology and Nephrology, vol.53, issue.1, pp.322-328, 2003. ,
DOI : 10.1016/S0090-4295(98)00655-4
Pygeum africanum for benign prostatic hyperplasia. (Cochrane Review) In: The Cochrane Library, 2002. ,
DOI : 10.1002/14651858.cd001044
Phytotherapy for benign prostatic hyperplasia, Public Health Nutr, vol.3, pp.459-72, 2000. ,
DOI : 10.1017/s1368980000000549
Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia, JAMA, vol.280, issue.18, pp.1604-1613, 1998. ,
DOI : 10.1001/jama.280.18.1604
Serenoa repens for benign prostatic hyperplasia (Cochrane Review) In: The Cochrane Library, 2001. ,
Antiproliferative Effect of Pygeum Africanum Extract on Rat Prostatic Fibroblasts, The Journal of Urology, vol.157, issue.6, pp.2381-2388, 1997. ,
DOI : 10.1016/S0022-5347(01)64785-2
Functional and anatomical effects of hormonally induced experimental prostate growth: A urodynamic model of benign prostatic hyperplasia (BPH) in the beagle, The Prostate, vol.46, issue.2, pp.156-163, 2004. ,
DOI : 10.1111/j.1464-410X.2000.tb16953.x